Latest News and Press Releases
Want to stay updated on the latest news?
-
SPOKANE, Wash., June 22, 2026 (GLOBE NEWSWIRE) -- Long-term data shows that lebrikizumab [Ebglyss], an injectable treatment for moderate to severe atopic dermatitis, sustains gains for up to 2...
-
The agency’s letter cited manufacturing-related items and raised no safety or efficacy concerns. Werschler, a Spokane dermatologist who has served as a clinical trial investigator in dermatology and...